HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3123-3128

  Sclafani, F ^a   Roy, A ^a   Cunningham, D ^a   Wotherspoon, A ^a   Peckitt, C ^a   De Castro, D Gonzalez ^a   Tabernero, J ^b   Glimelius, B ^c   Cervantes, A ^d   Eltahir, Z ^a   Oates, J ^a   Chau, I ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Biomarker; Cetuximab; Chemoradiotherapy; HER2; Neoadjuvant chemotherapy; Rectal cancer

Indexed keywords

B RAF KINASE; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM BIOPSY; RECTUM CANCER; RECTUM CARCINOMA; RECTUM RESECTION; TOTAL MESORECTAL EXCISION;

BIOMARKER; CETUXIMAB; CHEMORADIOTHERAPY; HER2; NEOADJUVANT CHEMOTHERAPY; RECTAL CANCER;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84888776574     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt408     Document Type: Article

References (22)

1. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004; 4: 361-370.
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
3. Hynes N, Stern D. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-184.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized controlled trial. N Engl J Med 2001; 344: 783-792.
5. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697.
6. Park DI, Kang MS, Oh SJ et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 2007; 22: 491-497.
7. Kavanagh DO, Chambers G, O'Grady L et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009; 9: 1.
8. Ramanathan RK, Hwang JJ, Zamboni WC et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 2004; 22: 858-865.
9. Marx AH, Burandt EC, Choschzick M et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Human Pathol 2010; 41: 1577-1585.
10. Dewdney A, Cunningham D, Tabernero J et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012; 30: 1620-1627.
11. RüschoffJ, Dietel M, Baretton G et al. HER2 Diagnostics in gastric cancer guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457: 299-307.
12. Benson AB, 3rd, Guillem JG, Minsky BD. Have the changes in treatment of rectal cancer made a significant difference to our patients? Oncology 2011; 25: 1323-1329.
13. Clark JW, Niedzwiecki D, Hollis D et al. Phase II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy. ASCO Annual Meeting Proc 2003; 22: A-3584.
14. Conradi LC, Styczen H, Sprenger T et al. Frequency of HER-2 positivity in rectal cancer and prognosis. Am J Surg Pathol 2013; 37: 522-531.
15. Al-Kuraya K, Novotny H, Bavi P et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 2007; 60: 768-772.
16. Vance GH, Barry TS, Bloom KJ et al. Genetic heterogeneity in HER2 testing in breast cancer: anel summary and guidelines. Arch Pathol Lab Med 2009; 133: 611-612.
17. Yoon HH, Shi Q, Sukov WR et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol 2012; 30: 3932-3938.
18. Owens MA, Horten BC, Da Silva MM et al. HER2 Amplification ratios by fluorescence in situ hybridization and correlation with immunoistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63-69.
19. Ross JS, Fletcher JA, Linette GP et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-325.
20. Spitzner M, Emons G, Kramer F et al. A gene expression signature for chemoradiosensitivity of colorectal cancer cells. Int J Radiat Oncol Biol Phys 2010; 78: 1184-1192.
21. Yonesaka K, Zejnullahu K, Okamoto I et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3: 99ra86.
22. Bertotti A, Migliardi G, Galimi F et al. A molecularly annotated platform of patientderived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1: 508-523.